Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.

Shadman M, Burke JM, Cultrera J, Yimer HA, Zafar SF, Misleh J, Rao SS, Farber CM, Cohen A, Yao H, Idoine A, An Q, Flinn IW, Sharman JP

Open source

DOI: 10.1182/bloodadvances.2024015493
Published: 2025 Aug 26
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2024015493,
  title = {Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.},
  author = {Shadman M and Burke JM and Cultrera J and Yimer HA and Zafar SF and Misleh J and Rao SS and Farber CM and Cohen A and Yao H and Idoine A and An Q and Flinn IW and Sharman JP},
  year = {2025},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2024015493},
  url = {https://doi.org/10.1182/bloodadvances.2024015493}
}

RIS

TY  - JOUR
TI  - Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.
AU  - Shadman M
AU  - Burke JM
AU  - Cultrera J
AU  - Yimer HA
AU  - Zafar SF
AU  - Misleh J
AU  - Rao SS
AU  - Farber CM
AU  - Cohen A
AU  - Yao H
AU  - Idoine A
AU  - An Q
AU  - Flinn IW
AU  - Sharman JP
PY  - 2025
JO  - Blood advances
DO  - 10.1182/bloodadvances.2024015493
UR  - https://doi.org/10.1182/bloodadvances.2024015493
ER  -

APA

M, S., JM, B., J, C., HA, Y., SF, Z., J, M., SS, R., CM, F., A, C., H, Y., A, I., Q, A., IW, F., & JP, S. (2025). Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.. Blood advances. https://doi.org/10.1182/bloodadvances.2024015493

Source records

pubmed · retrieved 2026-09-26T23:15:51.734Z